Navigation Links
ASU embarks on next phase of an effort to rapidly assess radiation dose
Date:10/6/2011

TEMPE, Ariz.--Arizona State University has announced today it is entering the next phase of a multi-million, multi-institutional research project to develop technologies that would rapidly measure an individual's level of exposure to radiation in the event of a radiological or nuclear incident.

The project will enter a $5 million contract option as part of a potential $35.44 million project funded by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to extend feasibility testing for the development of a prototype that will measure gene expression in individuals exposed to abnormal levels of radiation.

Currently, no rapid, FDA cleared, high-throughput system exists to measure the radiation dose of individuals within a large population.

"As Japan's tsunami and resulting nuclear crisis has demonstrated, there is an urgent societal need to rapidly assess an at risk population's exposure to radiation," said Lee Cheatham, PhD, deputy director of the Biodesign Institute and lead investigator of the project. "Our ultimate goal is to develop a diagnostic system that would ensure that medical responders have the information necessary to provide appropriate medical treatment and ensure human health and safety."

ASU will continue to oversee the research program management, coordination and integration necessary for effective development of the technology, which will develop a high-throughput system for radiation biodosimetry that is capable of processing a high volume of blood samples per day for gene expression analysis on an automated liquid handling and imaging platform consistent with FDA guidelines.

Developing the system requires utilizing a biomarker signature set based on gene expression markers. This set of markers will provide a distinct indicator for the level of absorbed radiation. Along with Biodesign Institute biomarker research expert Dr. Joshua LaBaer, director of the institute's Virginia G. Piper Center for Personalized Diagnostics, will be collaborators with extensive experience in researching radiation responsive genes and development of microassay reagents and imagers, including: Sally Amundson, PhD, at Columbia University Medical Center, Bruce Seligmann, PhD, founder and CSO at HTG Molecular Diagnostics, Inc. and Amelia Bartholomew, MD, MHP, FACS at University of Illinois, Chicago.

"We are honored to be part of this multi-institutional program and believe our work with ASU has further established HTG's dynamic offerings," said T.J. Johnson, Chief Executive Officer, HTG Molecular Diagnostics.

The ASU effort is part of a BARDA initiative to feed the pipeline for advanced development, manufacturing, and regulatory activities that would position ASU's biodosimetry device for potential use in human triage and treatment decisions.


'/>"/>

Contact: Joe Caspermeyer
joseph.caspermeyer@asu.edu
480-727-0369
Arizona State University
Source:Eurekalert

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: